Can You Take Mounjaro With Rheumatoid Arthritis? - Guide | Cured Pharmacy

Can You Take Mounjaro With Rheumatoid Arthritis?

Mounjaro Weight Loss Injections (Tirzepatide) KwikPen

Featured Product

Mounjaro Weight Loss Injections (Tirzepatide) KwikPen

From £145.00£124.99UK-based prescribers · Discreet delivery · Free private prescription
Start Assessment →✓ Lowest price guarantee
DISCOUNT CODE: FIRST20

£20 off for new patients

Tarun Kumar, Prescribing Pharmacist at Cured Pharmacy

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Reviewed on: 16 June 2026

Last Updated: 12 August 2026

If you are living with rheumatoid arthritis and also struggling with your weight, you may have heard about Mounjaro and wondered whether it could be an option for you. This is a completely understandable question, because managing two complex health conditions at the same time requires careful thought, particularly when it comes to medications and how they interact with one another. The good news is that, for many people with rheumatoid arthritis, Mounjaro is not automatically ruled out — but there are important considerations that need to be worked through with a qualified prescriber before you begin.

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today.

Once you complete a short online assessment, you will be able to choose your preferred treatment and quantity from a list of safe, medically approved options tailored to you.

Start My AssessmentReturning Customer?Log In to Your Account

Quick Summary

Mounjaro (tirzepatide) is a weekly injection approved in the UK for weight management. For people with rheumatoid arthritis, it is not automatically contraindicated, but individual assessment is essential given the potential interactions with certain RA medications and the impact of active disease on treatment suitability.

  • Rheumatoid arthritis alone is not a reason to avoid Mounjaro, but a full medical review is required
  • Some RA medications, such as methotrexate and NSAIDs, may need careful monitoring alongside Mounjaro
  • Weight loss achieved through Mounjaro may actually benefit people with RA by reducing joint load
  • Tirzepatide may have mild anti-inflammatory properties that could be indirectly helpful
  • Always consult a qualified UK prescriber before starting Mounjaro alongside any existing RA treatment

Mounjaro & Rheumatoid Arthritis Suitability Checker

Answer a few quick questions to see whether Mounjaro may be appropriate to discuss with your prescriber. This is not medical advice — always consult a healthcare professional.

1. Is your rheumatoid arthritis currently well controlled?

2. Do you take methotrexate or biologic medications for your RA?

3. Do you have a BMI of 30 or above (or 27+ with a weight-related condition)?

4. Do you have pancreatitis or a history of thyroid cancer?

Table of Contents

  1. What Is Mounjaro and How Does It Work?
  2. Can You Take Mounjaro With Rheumatoid Arthritis?
  3. Mounjaro and Common RA Medications: What You Need to Know
  4. How Weight Loss From Mounjaro May Benefit Rheumatoid Arthritis
  5. Risks and Considerations When Managing Both Conditions
  6. How to Get Started With Mounjaro Safely in the UK
  7. RA Medication and Mounjaro Compatibility Overview
  8. Key Takeaways
  9. When to Seek Professional Advice
  10. Scientific References
  11. Frequently Asked Questions

What Is Mounjaro and How Does It Work?

Mounjaro is the brand name for tirzepatide, a dual-action injectable medication that works by mimicking two gut hormones: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). These hormones help regulate blood sugar, reduce appetite, slow gastric emptying, and promote feelings of fullness after eating. It was originally developed for type 2 diabetes but has since been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for weight management in adults with a BMI of 30 or above, or 27 and above with at least one weight-related health condition.

Mounjaro is administered once weekly as a subcutaneous injection and comes in a range of doses, starting at 2.5 mg and potentially increasing up to 15 mg depending on individual response and tolerability. Clinical trials, including the SURMOUNT programme, have demonstrated remarkable results, with participants losing on average between 15 and 22 percent of their body weight over 72 weeks. This positions Mounjaro as one of the most effective weight loss treatments available in the UK today.

The mechanism goes beyond simple calorie restriction. Tirzepatide also appears to reduce systemic inflammation markers such as C-reactive protein (CRP) and interleukin-6 (IL-6), which are both significant in the pathology of rheumatoid arthritis. This is an area that researchers were actively investigating in 2026, with emerging data suggesting potential broader benefits for people living with inflammatory conditions.

  • Mounjaro mimics GLP-1 and GIP hormones to reduce appetite and regulate blood sugar
  • Administered as a once-weekly subcutaneous injection
  • MHRA-approved in the UK for weight management
  • Shown to produce significant weight loss in clinical trials
  • May have secondary effects on inflammatory markers relevant to RA

Can You Take Mounjaro With Rheumatoid Arthritis? Understanding the Safety Picture

Can you take Mounjaro with rheumatoid arthritis? The straightforward answer is that rheumatoid arthritis is not listed as a contraindication to Mounjaro in the UK prescribing information. This means that having RA does not automatically disqualify you from using this medication. However, the picture is more nuanced than a simple yes or no. Whether Mounjaro is appropriate for you will depend on the severity of your RA, whether your disease is currently stable or in an active flare, the specific medications you are taking to manage your RA, your kidney and liver function, and a range of other individual health factors.

Rheumatoid arthritis is a systemic autoimmune condition, which means it does not only affect the joints. It causes widespread inflammation that can impact organs including the heart, lungs, kidneys, and gastrointestinal system. This systemic inflammatory burden also contributes to a higher risk of cardiovascular disease and metabolic disorders, including obesity and type 2 diabetes. This is precisely why weight management is so important for people living with RA — and why Mounjaro may actually offer real benefits for this population.

Active RA flares can complicate the decision to start a new medication. During a flare, your body is already under significant physiological stress. Starting Mounjaro at this time may make it harder to attribute any new symptoms — such as nausea or fatigue — to the correct cause. Most prescribers in the UK would recommend stabilising your RA first before introducing Mounjaro.

  • RA is not an absolute contraindication to Mounjaro
  • Suitability depends on disease stability, organ function, and current medication regimen
  • Systemic inflammation from RA may increase metabolic disease risk, reinforcing the case for weight management
  • Active flares are generally not the ideal time to start a new treatment
  • Individual clinical assessment is always required before starting Mounjaro

Mounjaro and Common RA Medications: What You Need to Know

One of the most pressing concerns for people with rheumatoid arthritis who are considering Mounjaro is how it might interact with their existing RA treatment regimen. RA is typically managed with a range of medications including disease-modifying antirheumatic drugs (DMARDs) such as methotrexate, hydroxychloroquine, and sulfasalazine, biologic therapies such as adalimumab, etanercept, and tocilizumab, and non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and naproxen. Understanding how each of these interacts with Mounjaro is crucial for safe co-prescribing.

Methotrexate is one of the most commonly prescribed DMARDs and deserves particular attention. There is no direct pharmacokinetic interaction between tirzepatide and methotrexate documented in the current prescribing literature. However, both medications can have effects on gastrointestinal function, liver enzymes, and kidney clearance. Mounjaro slows gastric emptying, which can theoretically affect the absorption of oral medications taken at the same time. This means the timing of oral DMARD doses relative to Mounjaro injections may need consideration, and liver function should be monitored more closely in people taking both.

Biologic therapies work by targeting specific parts of the immune system. There is no established direct interaction between biologics and tirzepatide, but the immunological context is worth flagging with your prescriber. NSAIDs, frequently used for pain and stiffness, are associated with kidney stress and gastrointestinal irritation — two areas that can also be affected by Mounjaro. Using both together warrants careful monitoring of kidney function. Corticosteroids such as prednisolone, used in RA for flare management, can raise blood sugar levels, which is relevant when using a glucose-regulating medication like Mounjaro.

  • No direct pharmacokinetic interaction between tirzepatide and most RA drugs is currently documented
  • Mounjaro's slowing of gastric emptying may affect absorption of oral RA medications
  • Liver function monitoring is advisable for those on both Mounjaro and methotrexate
  • NSAIDs and Mounjaro together require kidney function monitoring
  • Corticosteroid-induced blood sugar rises should be considered in the context of tirzepatide use

How Weight Loss From Mounjaro May Benefit Rheumatoid Arthritis

This is where the conversation becomes genuinely encouraging. Excess body weight is a significant aggravating factor in rheumatoid arthritis. Adipose tissue — particularly visceral fat — is metabolically active and secretes pro-inflammatory cytokines such as TNF-alpha, IL-6, and leptin. These are some of the very same inflammatory mediators that drive RA joint damage. For many people with RA, weight is not just a comfort issue — it is a disease management issue.

Achieving meaningful weight loss through Mounjaro can reduce mechanical load on inflamed joints, particularly in the knees, hips, and lower back. Research consistently shows that every kilogram of body weight lost reduces knee joint load by approximately four kilograms during walking. For someone losing 10 to 20 kg with Mounjaro, this translates into an enormous reduction in daily joint stress. This alone can lead to measurable improvements in pain scores, mobility, and quality of life for people with joint pain and arthritis.

Beyond the mechanical benefits, weight loss has been shown to lower systemic inflammatory markers including CRP and erythrocyte sedimentation rate (ESR), both of which are used to monitor RA disease activity. A reduction in these markers may translate into a lower disease activity score (DAS28), which is the standard clinical tool used to assess RA severity in UK rheumatology clinics. Some patients even find their RA medication requirements reduce following significant weight loss, though this should never be adjusted without specialist guidance.

  • Visceral fat secretes inflammatory cytokines that worsen RA disease activity
  • Every kilogram lost reduces knee joint load by approximately four kilograms
  • Weight loss can lower CRP, ESR, and potentially improve DAS28 scores
  • Reduced joint load may lead to better mobility and reduced pain
  • Some patients may see indirect improvements in RA control following significant weight loss

Risks and Considerations When Managing Both Conditions

While the potential benefits of Mounjaro for people with rheumatoid arthritis are real, there are also risks and practical challenges that must be taken seriously. The most common side effects of Mounjaro are gastrointestinal in nature — nausea, vomiting, diarrhoea, constipation, and abdominal discomfort. People with RA who are also taking NSAIDs, methotrexate, or corticosteroids already face an elevated risk of gastrointestinal irritation. Combining these effects may increase discomfort, particularly in the early weeks of Mounjaro treatment when doses are being escalated.

Dehydration is another consideration. Vomiting or diarrhoea caused by Mounjaro — especially in the early phase — can lead to dehydration, which in turn reduces kidney perfusion. For people on NSAIDs or certain RA biologics that already place demands on kidney function, this can be clinically significant. Staying well hydrated and being aware of the signs of dehydration is important for anyone starting Mounjaro, but especially those with RA.

Muscle loss is a lesser-discussed concern. Rapid weight loss can include loss of lean muscle mass, which may worsen the muscle weakness and fatigue that many people with RA already experience. Maintaining adequate protein intake and incorporating appropriate physical activity — where RA permits — can help preserve muscle mass during treatment. It is also worth noting that Mounjaro should not be used during pregnancy, and people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not use it.

  • GI side effects from Mounjaro may compound those caused by RA medications
  • Dehydration risk increases when using Mounjaro alongside NSAIDs or biologics
  • Muscle mass preservation requires adequate protein intake and appropriate activity
  • Mounjaro is contraindicated in pregnancy and certain thyroid cancer histories
  • Regular monitoring by a prescriber is essential throughout treatment

How to Get Started With Mounjaro Safely in the UK

If you have rheumatoid arthritis and are considering Mounjaro for weight management, the process in the UK starts with a thorough medical consultation. This can be done through your GP, a specialist obesity service, or a registered online pharmacy that offers prescribing services such as Cured Pharmacy. The consultation will involve a review of your BMI, current health conditions, medications, and medical history. A prescriber will also want to know about the stability of your RA, your kidney and liver function results, and whether you are under the care of a rheumatologist.

If Mounjaro is deemed appropriate, treatment typically begins at 2.5 mg per week for four weeks, then increases gradually to 5 mg and beyond, depending on your response. The slow titration is designed to minimise side effects and allow your body to adapt. During this period, it is particularly important for people with RA to stay in close contact with both their rheumatologist and their Mounjaro prescriber so that any new symptoms can be appropriately attributed and managed.

In 2026, access to weight loss treatments like Mounjaro through regulated online services has become increasingly streamlined in the UK. Reputable services will always conduct a proper assessment, screen for contraindications, and provide ongoing monitoring support. You should be cautious of any service that offers Mounjaro without a consultation or medical assessment, as this poses serious risks to your health.

  • Start with a full medical consultation that covers your RA history and current medications
  • Inform both your rheumatologist and your Mounjaro prescriber about all treatments you are taking
  • Treatment begins at a low dose (2.5 mg) and increases gradually over several weeks
  • Regular monitoring is essential, particularly of liver and kidney function
  • Use only regulated and licensed UK prescribing services for safe access

RA Medication and Mounjaro Compatibility: A Practical Overview

RA Medication Type Interaction Risk With Mounjaro Key Monitoring Requirement
Methotrexate DMARD Low to moderate — no direct interaction, but absorption timing and liver function need attention Liver function tests, GI symptoms
Hydroxychloroquine DMARD Low — minimal interaction risk documented Routine monitoring, blood glucose if diabetic
Sulfasalazine DMARD Low — no significant interaction known GI tolerance, routine bloods
Adalimumab (Humira) Biologic (TNF inhibitor) Low — no direct pharmacological interaction Infection monitoring, injection site awareness
Tocilizumab (Actemra) Biologic (IL-6 inhibitor) Low — no direct interaction; both affect IL-6 pathway indirectly Liver enzymes, lipid profile
Ibuprofen / Naproxen NSAID Moderate — both can stress kidneys; dehydration risk elevated Kidney function (eGFR), hydration status
Prednisolone Corticosteroid Moderate — steroids raise blood glucose, Mounjaro lowers it; risk of fluctuations Blood glucose levels, weight changes
Leflunomide DMARD Low to moderate — both affect liver; enhanced hepatotoxicity monitoring required Liver function tests, GI side effects

Key Takeaways

  • Rheumatoid arthritis is not a contraindication to Mounjaro, but each case must be individually assessed by a qualified UK prescriber
  • Mounjaro may offer indirect benefits for RA by reducing systemic inflammation and joint load through weight loss
  • Careful monitoring of liver and kidney function is essential when combining Mounjaro with common RA medications such as methotrexate or NSAIDs
  • Gastrointestinal side effects from Mounjaro and RA medications may compound — report any concerning symptoms to your prescriber promptly
  • Always ensure your rheumatologist and prescribing pharmacist or GP are both aware of your full medication regimen before starting Mounjaro

When to Seek Professional Advice

You should seek professional advice before starting Mounjaro if you have rheumatoid arthritis, regardless of how stable your condition currently feels. A prescriber needs to review your complete medical history, current medications, and relevant blood test results. This is especially important if you are taking methotrexate, leflunomide, any biologic therapy, regular NSAIDs, or long-term corticosteroids.

You should also contact your prescriber or GP promptly if, after starting Mounjaro, you notice significant nausea or vomiting that is affecting your ability to take your RA medications reliably, signs of dehydration such as dark urine, dizziness, or reduced urination, any sudden worsening of RA symptoms or a new flare, unexplained fatigue or muscle weakness beyond what you normally experience, or any abdominal pain that could suggest pancreatitis, which is a rare but serious side effect of Mounjaro.

If you are unsure whether Mounjaro is right for you, completing a structured online medical assessment with a regulated UK pharmacy is a sensible first step. Explore weight loss options through a service staffed by qualified UK prescribers who can review your full health picture before making any recommendation.

Scientific References

  1. Electronic Medicines Compendium (eMC): Mounjaro (tirzepatide) Summary of Product Characteristics. Eli Lilly and Company Ltd, UK. [Accessed 12 August 2026]
  2. National Institute for Health and Care Excellence (NICE): Tirzepatide for managing overweight and obesity. Technology Appraisal Guidance TA1026. NICE, 2024. [Accessed 12 August 2026]
  3. Versus Arthritis: Rheumatoid Arthritis — Condition Information and Treatment Overview. Versus Arthritis, UK. [Accessed 12 August 2026]
  4. NICE Guideline NG100: Rheumatoid arthritis in adults: management, National Institute for Health and Care Excellence, 2018 (updated 2020) [Accessed 12 August 2026]
  5. Mounjaro 2.5 mg solution for injection Summary of Product Characteristics, Electronic Medicines Compendium (EMC), Eli Lilly, 2023 [Accessed 12 August 2026]
  6. Lingvay I et al., Tirzepatide for type 2 diabetes or weight management in people with cardiometabolic risk, BMJ, 2023 [Accessed 12 August 2026]
  7. NICE Technology Appraisal TA924: Tirzepatide for managing overweight and obesity, National Institute for Health and Care Excellence, 2024 [Accessed 12 August 2026]
  8. Sparks JA et al., Obesity, lifestyle factors, and risk of rheumatoid arthritis, Annals of the Rheumatic Diseases, 2020 [Accessed 12 August 2026]
  9. Rheumatoid Arthritis condition information including comorbidities and weight management, Versus Arthritis, 2023 [Accessed 12 August 2026]

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today.

Once you complete a short online assessment, you will be able to choose your preferred treatment and quantity from a list of safe, medically approved options tailored to you.

Start My AssessmentReturning Customer?Log In to Your Account

Frequently Asked Questions

Can you take Mounjaro with methotrexate for rheumatoid arthritis?

Taking Mounjaro with methotrexate for rheumatoid arthritis does not appear to cause a direct drug interaction, but caution is still advised. Both medications can affect the liver and digestive system, so your prescriber should review your full medication list, monitor liver function, and assess your overall health before starting Mounjaro alongside methotrexate.

Is it safe to take Mounjaro if you have rheumatoid arthritis?

Taking Mounjaro when you have rheumatoid arthritis may be safe for many people, but it depends on individual health factors. Rheumatoid arthritis alone is not a contraindication to Mounjaro. However, your prescriber needs to assess your kidney function, other medications, and any active flares before deciding whether Mounjaro is appropriate for you.

Can Mounjaro help reduce inflammation in rheumatoid arthritis?

Mounjaro's role in reducing rheumatoid arthritis inflammation is not yet fully established, though emerging research suggests tirzepatide, Mounjaro's active ingredient, may have modest anti-inflammatory effects. Weight loss achieved through Mounjaro can also reduce mechanical stress on joints and lower systemic inflammatory markers, potentially offering indirect benefits for people with rheumatoid arthritis.

How long does Mounjaro take to work for weight loss?

Mounjaro typically begins to show weight loss results within the first four to eight weeks of treatment, with more significant results becoming apparent after three to six months. Clinical trials show that many people lose between 15 and 22 percent of their body weight over approximately 72 weeks when combined with lifestyle changes.

Back to blog